West Pharmaceutical Services (WST) - FREE Research Report

Morel Donald E Jr who is Chair of the Board & CEO at West Pharmaceutical Services sold 5,000 shares at $49.26 on Dec. 2, 2013. Following this transaction, the Chair of the Board & CEO owned 965,801 shares meaning that the stake was reduced by 0.52% with the 5,000-share transaction.

The shares most recently traded at $49.45, up $0.19, or 0.38% since the insider transaction. Historical insider transactions for West Pharmaceutical Services go as follows:

  • 4-Week # shares sold: 55,302
  • 12-Week # shares sold: 55,302
  • 24-Week # shares sold: 68,485

The average volume for West Pharmaceutical Services has been 249,100 shares per day over the past 30 days. West Pharmaceutical Services has a market cap of $3.5 billion and is part of the health care sector and health services industry. Shares are up 79.69% year-to-date as of the close of trading on Monday.

West Pharmaceutical Services, Inc. manufactures and sells components and systems for injectable drug delivery and plastic packaging, as well as delivery system components for the pharmaceutical, healthcare, and consumer products industries. The stock currently has a dividend yield of 0.8%. The company has a P/E ratio of 32.2. Currently there is 1 analyst that rates West Pharmaceutical Services a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WST - FREE

TheStreet Quant Ratings rates West Pharmaceutical Services as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full West Pharmaceutical Services Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

A Sale of Citrix Would Complete Multi-Year Effort for Activist Elliott Management

Ranking the Activists for Proxy Season 2016

Symantec to Buy LifeLock in $2.3 Billion Cybersecurity Transformation

Own a Piece of the Rock -- and Sun

Why Activist Investors Won't Touch the Big Buyout Shops